Former Chief Medical Officer and Assistant Secretary for Health Affairs of the U.S. Department of Homeland Security, Dr. Jeffrey Runge, Appointed to Aditxt Board of Directors
Aditxt, Inc. (ADTX)
Company Research
Source: GlobeNewswire
Dr. Runge brings 35 years’ experience as an Emergency Medicine Physician, Federal Government Executive and Public Policy Strategist Mountain View, CA, Oct. 01, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced that it has appointed Dr. Jeffrey Runge, MD, FACEP, to the Company’s Board of Directors effective as of July 16, 2020. Dr. Runge will be an independent director in accordance with the applicable rules of the Nasdaq Stock Market LLC. Dr. Runge has over?35-years of clinical, research, leadership, and administrative experience, as well as being a board-certified physician in emergency medicine. Most notably, from 2001-2005 Dr. Runge served as the U.S. Department of Homeland Security’s (DHS) first Chief Medical Officer and Assistant Secreta
Show less
Read more
Impact Snapshot
Event Time:
ADTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADTX alerts
High impacting Aditxt, Inc. news events
Weekly update
A roundup of the hottest topics
ADTX
News
- Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 [Yahoo! Finance]Yahoo! Finance
- Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023PR Newswire
- Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal [Yahoo! Finance]Yahoo! Finance
- Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-CalPR Newswire
- For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy [Yahoo! Finance]Yahoo! Finance
ADTX
Sec Filings
- 3/11/24 - Form 8-K
- 3/4/24 - Form 425
- 3/4/24 - Form 8-K
- ADTX's page on the SEC website